Healthcare software company EMIS Group booked impressive fundamentals for the first half of 2019.
The Group’s total revenue grew 7% on a year-on-year comparison, up to £79.8 million. While reported operating profit dipped 3%, adjusted operating profit grew 8%, from £16.8 million to £18.2 million.
The Company had a positive set of results to report to its shareholders, with adjusted and reported earnings per share up by 12% and 3% respectively. The Group reported an interim dividend of 15.6p a share, up 10% on H1 2018.
The downfalls in EMIS Group’s results were regarding its cash flow, its adjusted cash from operations dipped 18% on-year to £27.5 million, and its net cash dropped 17% to £26.7 million.
EMIS Group comments
Andy Thorburn, Chief Executive Officer, said,
“We have continued to demonstrate good progress in the first half of 2019, delivering positive results in line with the Board’s expectations, with both revenue and adjusted operating profit ahead of the comparative period.”
“We are well positioned to secure our place on the GP IT Futures framework for GP software in England and continue to invest in patient-facing technology and the next generation EMIS-X platform. With our balance of technology, clinical standards and a continuously improving technical environment, the Group is well placed to deliver on its growth and margin targets.”
Investor notes
The Company’s shares have so far rallied 1.26% or 14.00p to 1,126.00p 30/08/19 11:38 BST. The Group’s p/e ratio is 23.46 and its dividend yield stands at 2.53%.
Elsewhere in health and medical news, there have been updates from; OptiBiotix Health PLC (LON: OPTI) NMC Health (LON: NMC), Astrazeneca plc (LON: AZN) and ValiRx Plc (LON:VAL).
